Surmodics Management
Management criteria checks 2/4
Surmodics' CEO is Gary Maharaj, appointed in Dec 2010, has a tenure of 14.08 years. total yearly compensation is $3.67M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 1.34% of the company’s shares, worth $6.82M. The average tenure of the management team and the board of directors is 6.7 years and 14.1 years respectively.
Key information
Gary Maharaj
Chief executive officer
US$3.7m
Total compensation
CEO salary percentage | 17.7% |
CEO tenure | 14.1yrs |
CEO ownership | 1.3% |
Management average tenure | 6.7yrs |
Board average tenure | 14.1yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump
Jun 06Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 30Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2024 | n/a | n/a | -US$14m |
Sep 30 2024 | US$4m | US$647k | -US$12m |
Jun 30 2024 | n/a | n/a | -US$1m |
Mar 31 2024 | n/a | n/a | US$14m |
Dec 31 2023 | n/a | n/a | US$6m |
Sep 30 2023 | US$4m | US$640k | -US$2m |
Jun 30 2023 | n/a | n/a | -US$23m |
Mar 31 2023 | n/a | n/a | -US$36m |
Dec 31 2022 | n/a | n/a | -US$32m |
Sep 30 2022 | US$3m | US$620k | -US$27m |
Jun 30 2022 | n/a | n/a | -US$13m |
Mar 31 2022 | n/a | n/a | -US$10m |
Dec 31 2021 | n/a | n/a | US$2m |
Sep 30 2021 | US$3m | US$602k | US$4m |
Jun 30 2021 | n/a | n/a | US$2m |
Mar 31 2021 | n/a | n/a | US$7m |
Dec 31 2020 | n/a | n/a | US$701k |
Sep 30 2020 | US$3m | US$585k | US$1m |
Jun 30 2020 | n/a | n/a | US$8m |
Mar 31 2020 | n/a | n/a | US$7m |
Dec 31 2019 | n/a | n/a | US$6m |
Sep 30 2019 | US$2m | US$568k | US$8m |
Jun 30 2019 | n/a | n/a | US$2m |
Mar 31 2019 | n/a | n/a | -US$2m |
Dec 31 2018 | n/a | n/a | -US$2m |
Sep 30 2018 | US$2m | US$551k | -US$4m |
Compensation vs Market: Gary's total compensation ($USD3.67M) is above average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Maharaj (61 yo)
14.1yrs
Tenure
US$3,665,496
Compensation
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 14.1yrs | US$3.67m | 1.34% $ 6.8m | |
Senior VP of Finance & Information Technology and CFO | 6.7yrs | US$1.34m | 0.47% $ 2.4m | |
Senior VP of Legal | 4.7yrs | US$1.15m | 0.15% $ 746.6k | |
Senior VP & President of Medical Device Coatings | 20.3yrs | US$1.13m | 0.37% $ 1.9m | |
Senior VP & President of Vascular Interventions | 2.7yrs | US$1.52m | 0.24% $ 1.2m | |
Corporate Controller | 6.7yrs | no data | 0.057% $ 289.4k | |
Director of Corporate Development | no data | no data | no data | |
Senior VP of Human Resources & President of In Vitro Diagnostics | 4.8yrs | US$970.92k | 0.43% $ 2.2m |
6.7yrs
Average Tenure
59yo
Average Age
Experienced Management: SRDX's management team is seasoned and experienced (6.7 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 14.1yrs | US$3.67m | 1.34% $ 6.8m | |
Independent Director | 14yrs | US$185.00k | 0.27% $ 1.4m | |
Independent Non-Executive Chair of the Board | 17yrs | US$234.00k | 0.14% $ 708.1k | |
Independent Director | 23yrs | US$176.50k | 0.20% $ 1.0m | |
Independent Director | 7.8yrs | US$181.50k | 0.094% $ 477.4k |
14.1yrs
Average Tenure
68yo
Average Age
Experienced Board: SRDX's board of directors are seasoned and experienced ( 14.1 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/31 23:40 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Surmodics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Argus Research Company |
Daniel Owczarski | Avondale Partners |
Michael Petusky | Barrington Research Associates, Inc. |